Akari Therapeutics Plc (AKTX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Akari Therapeutics Plc is a pre-revenue biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) following its November 2024 acquisition of Peak Bio, Inc. The company has suspended internal development of its legacy programs (nomacopan and PAS-nomacopan) to prioritize its ADC platform, specifically the lead candidate AKTX-101. The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(6.4) million | $(2.9) million | $(12.0) million | $(16.0) million |
| Operating Loss | $(7.4) million | $(2.9) million | $(14.0) million | $(16.4) million |
| Cash and Restricted Cash | $2.5 million | $2.2 million | $2.5 million (End of Period) | $2.2 million (End of Period) |
| Accumulated Deficit | $(259.3) million | $(243.5) million | $(259.3) million | $(243.5) million |
| Operating Cash Flow | Not provided for Q3 | Not provided for Q3 | $(7.5) million | $(10.4) million |
| Financing Cash Flow | Not provided for Q3 | Not provided for Q3 | $7.4 million | $8.8 million |
Note: All figures in millions unless otherwise noted. The filing does not provide specific margin data as the company has no revenue.
Material Changes vs. Prior Period
- Impairment Loss: The company recorded a non-cash impairment loss of $5.18 million in Q3 2025 related to the PHP-303 asset. This was due to the reprioritization of resources to the ADC platform and the inability to find a collaborative partner for PHP-303. No such impairment was recorded in the prior year period.
- Operating Expenses: Total operating expenses for the nine months ended September 30, 2025, decreased by approximately $2.3 million compared to the prior year period. This reduction is primarily driven by the suspension of legacy programs (nomacopan and PAS-nomacopan) and the absence of merger-related costs incurred in 2024.
- Debt and Financing: The company engaged in significant financing activities in 2025, including a March 2025 Private Placement and an August 2025 Note Offering. In Q3 2025, the company recognized a $1.0 million loss on debt extinguishment related to the modification of convertible notes and the exchange of related-party debt.
- Gain on Settlement: The company recognized a $2.0 million gain on the settlement of current liabilities during the nine months ended September 30, 2025, resulting from settlements with vendors and debt extinguishment.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Cash on hand ($2.5 million) is insufficient to fund operations for the next 12 months. The company expects to fund operations into December 2025 based on existing cash and a subsequent October 2025 financing.
- Recent Financing (Subsequent Event): On October 16, 2025, the company closed a registered direct offering raising $2.5 million in gross proceeds. Additionally, an Equity Line of Credit (ELOC) agreement with White Lion Capital was signed in August 2025, providing access to up to $25 million in funding, subject to conditions.
- Strategic Focus: The company is focusing exclusively on its ADC platform (AKTX-101) and seeking strategic partners for its legacy assets (nomacopan, PAS-nomacopan, and PHP-303).
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting as of December 31, 2024, which remained unremediated as of September 30, 2025. Remediation efforts are expected to begin in the third quarter of 2025.
- Legal Proceedings: The company is defending against a claim from a former employee regarding discretionary bonuses and has settled claims with former consultants for $0.4 million.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.5 million raised in the October 2025 offering to bridge the gap until the next funding round or commercial milestone.
- Debt Obligations: Review the terms of the August 2025 Notes and related-party debt, including maturity dates (2026) and potential dilution from conversion features.
- Going Concern Status: Assess the likelihood of securing additional capital given the substantial doubt expressed in the filing and the high dilution risk of future equity raises.
- Internal Controls: Monitor the progress of remediation efforts for the material weaknesses in internal controls over financial reporting.
- Asset Impairment: Confirm the status of the PHP-303 program and the potential for further impairments if no strategic partner is found.